Delayed London S.E. 07:36:32 2024-03-28 am EDT 5-day change 1st Jan Change
34.5 GBX -1.43% Intraday chart for Renalytix Plc -2.82% +122.58%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Horizonte subsidiary hit with debt injunction AN
Renalytix plc's KidneyIntelX Included in Final KDIGO 2024 Clinical Guideline for Chronic Kidney Disease CI
ADRs End Higher, ATRenew Inc. Climbs 26.9% DJ
Renalytix Raises $12 Million via Equity Placing to Extend Cash Runway MT
Renalytix shares sink on heavily discounted placing AN
Renalytix Targets $10 Million Equity Raise to Extend Cash Runway MT
ADRs End Higher, Renalytix PLC Climbs 41.4% DJ
The FTSE 100 Closes Down 0.5% as UK Budget Looms Large on the Horizon DJ
Renalytix Kicks Off Formal Sale Process Following Approach from Unnamed Diagnostics Company MT
Renalytix shares up as company commences formal sale process AN
Renalytix Expands US Coverage for Kidney Disease Test MT
Renalytix up as kidneyintelX.dkd authorised for US government contract AN
ADRs Close Higher; Airnet Technology Climbs 54% DJ
Earnings Flash (RNLX) RENALYTIX Posts Q2 Revenue $709,000 MT
Renalytix narrows annual loss but cash balance and revenue fall AN
ADRs Close Higher; Earlyworks Soars 188% DJ
Renalytix Plc Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2023 CI
ADRs End Lower; TC Biopharm Declines 28% DJ
ADRs End With Gains; TC BioPharm Climbs 38% DJ
Wall Street Set to Open Modestly Higher as S&P Hovers Just Above 5,000 MT
Renalytix up after US CMS issues draft local coverage determination AN
Centers for Medicare & Medicaid Services Publishes Draft Local Coverage Determination for Renalytix Plc's Kidneyintelx and Kidneyintelx.Dkd CI
ADRs Close Higher, Renalytix PLC Climbs 96.9% DJ
ADRs End Lower; Evaxion Biotech A/S Drops 45% DJ
Renalytix plc Announces Update on Kidneyintelx.Dkd Local Coverage Determination Consideration CI
Chart Renalytix Plc
More charts
Renalytix plc is a United Kingdom-based company, which is engaged in the development of artificial intelligence-enabled clinical diagnostic solutions for kidney disease. The Company is engaged in a field of bioprognosis for kidney health. The Company has engineered a solution that enables early-stage chronic kidney disease progression risk assessment. The Company’s lead product, KidneyIntelX platform, is designed to scale across kidney disease conditions beyond diabetic kidney disease. It is evaluating a range of indications in chronic kidney disease, cardio-renal disease, chronic kidney disease in diverse populations and COVID-related kidney disease. KidneyIntelX has been granted designation by the United States Food and Drug Administration and is designed to help make significant improvements in kidney disease prognosis, transplant management, clinical care, patient stratification for drug clinical trials, and drug target discovery.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
0.35
Average target price
-
Consensus

Quarterly revenue - Rate of surprise

  1. Stock
  2. Equities
  3. Stock Renalytix Plc - London S.E.
  4. News Renalytix Plc
  5. Renalytix Says Kidney Disease Test Valuable as Risk Decision Tool in Primary Care Setting